Global Neurological Disorder Drugs Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027
Date: May-2021 | Id: MACRC-64473 | Geographical Scope: Global | Publisher: HNY Research
The global Neurological Disorder Drugs market is expected to reach US$ XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on Mnemonics Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). By Market Verdors: Novartis AG GlaxoSmithKline plc Merck & Co. Bayer AG AstraZeneca Boehringer Ingelheim GmbH Teva Pharmaceutical By Types: Antipsychotic Hypnotic & Sedative Analgesics Anticoagulants Others By Applications: Hospital Clinic Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry. Key Reasons to Purchase To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape. Assess the production processes, major issues, and solutions to mitigate the development risk. To understand the most affecting driving and restraining forces in the market and its impact in the global market. Learn about the market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview 1.1 Study Scope and Definition 1.2 Research Methodology 1.2.1 Methodology/Research Approach 1.2.2 Data Source 1.3 Key Market Segments 1.4 Players Covered: Ranking by Neurological Disorder Drugs Revenue 1.5 Market Analysis by Type 1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2021 VS 2027 1.5.2 Antipsychotic 1.5.3 Hypnotic & Sedative 1.5.4 Analgesics 1.5.5 Anticoagulants 1.5.6 Others 1.6 Market by Application 1.6.1 Global Neurological Disorder Drugs Market Share by Application: 2022-2027 1.6.2 Hospital 1.6.3 Clinic 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2021 and 2022 Projections 1.7.2 Covid-19 Impact: Commodity Prices Indices 1.7.3 Covid-19 Impact: Global Major Government Policy 1.8 Study Objectives 1.9 Years Considered 2 Global Neurological Disorder Drugs Market Trends and Growth Strategy 2.1 Market Top Trends 2.2 Market Drivers 2.3 Market Challenges 2.4 Porter’s Five Forces Analysis 2.5 Market Growth Strategy 2.6 SWOT Analysis 3 Global Neurological Disorder Drugs Market Players Profiles 3.1 Novartis AG 3.1.1 Novartis AG Company Profile 3.1.2 Novartis AG Neurological Disorder Drugs Product Specification 3.1.3 Novartis AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.2 GlaxoSmithKline plc 3.2.1 GlaxoSmithKline plc Company Profile 3.2.2 GlaxoSmithKline plc Neurological Disorder Drugs Product Specification 3.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.3 Merck & Co. 3.3.1 Merck & Co. Company Profile 3.3.2 Merck & Co. Neurological Disorder Drugs Product Specification 3.3.3 Merck & Co. Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.4 Bayer AG 3.4.1 Bayer AG Company Profile 3.4.2 Bayer AG Neurological Disorder Drugs Product Specification 3.4.3 Bayer AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.5 AstraZeneca 3.5.1 AstraZeneca Company Profile 3.5.2 AstraZeneca Neurological Disorder Drugs Product Specification 3.5.3 AstraZeneca Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.6 Boehringer Ingelheim GmbH 3.6.1 Boehringer Ingelheim GmbH Company Profile 3.6.2 Boehringer Ingelheim GmbH Neurological Disorder Drugs Product Specification 3.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.7 Teva Pharmaceutical 3.7.1 Teva Pharmaceutical Company Profile 3.7.2 Teva Pharmaceutical Neurological Disorder Drugs Product Specification 3.7.3 Teva Pharmaceutical Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021) 4 Global Neurological Disorder Drugs Market Competition by Market Players 4.1 Global Neurological Disorder Drugs Production Capacity Market Share by Market Players (2016-2021) 4.2 Global Neurological Disorder Drugs Revenue Market Share by Market Players (2016-2021) 4.3 Global Neurological Disorder Drugs Average Price by Market Players (2016-2021) 5 Global Neurological Disorder Drugs Production by Regions (2016-2021) 5.1 North America 5.1.1 North America Neurological Disorder Drugs Market Size (2016-2021) 5.1.2 Neurological Disorder Drugs Key Players in North America (2016-2021) 5.1.3 North America Neurological Disorder Drugs Market Size by Type (2016-2021) 5.1.4 North America Neurological Disorder Drugs Market Size by Application (2016-2021) 5.2 East Asia 5.2.1 East Asia Neurological Disorder Drugs Market Size (2016-2021) 5.2.2 Neurological Disorder Drugs Key Players in East Asia (2016-2021) 5.2.3 East Asia Neurological Disorder Drugs Market Size by Type (2016-2021) 5.2.4 East Asia Neurological Disorder Drugs Market Size by Application (2016-2021) 5.3 Europe 5.3.1 Europe Neurological Disorder Drugs Market Size (2016-2021) 5.3.2 Neurological Disorder Drugs Key Players in Europe (2016-2021) 5.3.3 Europe Neurological Disorder Drugs Market Size by Type (2016-2021) 5.3.4 Europe Neurological Disorder Drugs Market Size by Application (2016-2021) 5.4 South Asia 5.4.1 South Asia Neurological Disorder Drugs Market Size (2016-2021) 5.4.2 Neurological Disorder Drugs Key Players in South Asia (2016-2021) 5.4.3 South Asia Neurological Disorder Drugs Market Size by Type (2016-2021) 5.4.4 South Asia Neurological Disorder Drugs Market Size by Application (2016-2021) 5.5 Southeast Asia 5.5.1 Southeast Asia Neurological Disorder Drugs Market Size (2016-2021) 5.5.2 Neurological Disorder Drugs Key Players in Southeast Asia (2016-2021) 5.5.3 Southeast Asia Neurological Disorder Drugs Market Size by Type (2016-2021) 5.5.4 Southeast Asia Neurological Disorder Drugs Market Size by Application (2016-2021) 5.6 Middle East 5.6.1 Middle East Neurological Disorder Drugs Market Size (2016-2021) 5.6.2 Neurological Disorder Drugs Key Players in Middle East (2016-2021) 5.6.3 Middle East Neurological Disorder Drugs Market Size by Type (2016-2021) 5.6.4 Middle East Neurological Disorder Drugs Market Size by Application (2016-2021) 5.7 Africa 5.7.1 Africa Neurological Disorder Drugs Market Size (2016-2021) 5.7.2 Neurological Disorder Drugs Key Players in Africa (2016-2021) 5.7.3 Africa Neurological Disorder Drugs Market Size by Type (2016-2021) 5.7.4 Africa Neurological Disorder Drugs Market Size by Application (2016-2021) 5.8 Oceania 5.8.1 Oceania Neurological Disorder Drugs Market Size (2016-2021) 5.8.2 Neurological Disorder Drugs Key Players in Oceania (2016-2021) 5.8.3 Oceania Neurological Disorder Drugs Market Size by Type (2016-2021) 5.8.4 Oceania Neurological Disorder Drugs Market Size by Application (2016-2021) 5.9 South America 5.9.1 South America Neurological Disorder Drugs Market Size (2016-2021) 5.9.2 Neurological Disorder Drugs Key Players in South America (2016-2021) 5.9.3 South America Neurological Disorder Drugs Market Size by Type (2016-2021) 5.9.4 South America Neurological Disorder Drugs Market Size by Application (2016-2021) 5.10 Rest of the World 5.10.1 Rest of the World Neurological Disorder Drugs Market Size (2016-2021) 5.10.2 Neurological Disorder Drugs Key Players in Rest of the World (2016-2021) 5.10.3 Rest of the World Neurological Disorder Drugs Market Size by Type (2016-2021) 5.10.4 Rest of the World Neurological Disorder Drugs Market Size by Application (2016-2021) 6 Global Neurological Disorder Drugs Consumption by Region (2016-2021) 6.1 North America 6.1.1 North America Neurological Disorder Drugs Consumption by Countries 6.1.2 United States 6.1.3 Canada 6.1.4 Mexico 6.2 East Asia 6.2.1 East Asia Neurological Disorder Drugs Consumption by Countries 6.2.2 China 6.2.3 Japan 6.2.4 South Korea 6.3 Europe 6.3.1 Europe Neurological Disorder Drugs Consumption by Countries 6.3.2 Germany 6.3.3 United Kingdom 6.3.4 France 6.3.5 Italy 6.3.6 Russia 6.3.7 Spain 6.3.8 Netherlands 6.3.9 Switzerland 6.3.10 Poland 6.4 South Asia 6.4.1 South Asia Neurological Disorder Drugs Consumption by Countries 6.4.2 India 6.5 Southeast Asia 6.5.1 Southeast Asia Neurological Disorder Drugs Consumption by Countries 6.5.2 Indonesia 6.5.3 Thailand 6.5.4 Singapore 6.5.5 Malaysia 6.5.6 Philippines 6.6 Middle East 6.6.1 Middle East Neurological Disorder Drugs Consumption by Countries 6.6.2 Turkey 6.6.3 Saudi Arabia 6.6.4 Iran 6.6.5 United Arab Emirates 6.7 Africa 6.7.1 Africa Neurological Disorder Drugs Consumption by Countries 6.7.2 Nigeria 6.7.3 South Africa 6.8 Oceania 6.8.1 Oceania Neurological Disorder Drugs Consumption by Countries 6.8.2 Australia 6.9 South America 6.9.1 South America Neurological Disorder Drugs Consumption by Countries 6.9.2 Brazil 6.9.3 Argentina 6.10 Rest of the World 6.10.1 Rest of the World Neurological Disorder Drugs Consumption by Countries 7 Global Neurological Disorder Drugs Production Forecast by Regions (2022-2027) 7.1 Global Forecasted Production of Neurological Disorder Drugs (2022-2027) 7.2 Global Forecasted Revenue of Neurological Disorder Drugs (2022-2027) 7.3 Global Forecasted Price of Neurological Disorder Drugs (2022-2027) 7.4 Global Forecasted Production of Neurological Disorder Drugs by Region (2022-2027) 7.4.1 North America Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.2 East Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.3 Europe Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.4 South Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.5 Southeast Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.6 Middle East Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.7 Africa Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.8 Oceania Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.9 South America Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.4.10 Rest of the World Neurological Disorder Drugs Production, Revenue Forecast (2022-2027) 7.5 Forecast by Type and by Application (2022-2027) 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027) 7.5.2 Global Forecasted Consumption of Neurological Disorder Drugs by Application (2022-2027) 8 Global Neurological Disorder Drugs Consumption Forecast by Regions (2022-2027) 8.1 North America Forecasted Consumption of Neurological Disorder Drugs by Country 8.2 East Asia Market Forecasted Consumption of Neurological Disorder Drugs by Country 8.3 Europe Market Forecasted Consumption of Neurological Disorder Drugs by Countriy 8.4 South Asia Forecasted Consumption of Neurological Disorder Drugs by Country 8.5 Southeast Asia Forecasted Consumption of Neurological Disorder Drugs by Country 8.6 Middle East Forecasted Consumption of Neurological Disorder Drugs by Country 8.7 Africa Forecasted Consumption of Neurological Disorder Drugs by Country 8.8 Oceania Forecasted Consumption of Neurological Disorder Drugs by Country 8.9 South America Forecasted Consumption of Neurological Disorder Drugs by Country 8.10 Rest of the world Forecasted Consumption of Neurological Disorder Drugs by Country 9 Global Neurological Disorder Drugs Sales by Type (2016-2027) 9.1 Global Neurological Disorder Drugs Historic Market Size by Type (2016-2021) 9.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2022-2027) 10 Global Neurological Disorder Drugs Consumption by Application (2016-2027) 10.1 Global Neurological Disorder Drugs Historic Market Size by Application (2016-2021) 10.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2022-2027) 11 Global Neurological Disorder Drugs Manufacturing Cost Analysis 11.1 Neurological Disorder Drugs Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.3 Manufacturing Process Analysis of Neurological Disorder Drugs 12 Global Neurological Disorder Drugs Marketing Channel, Distributors, Customers and Supply Chain 12.1 Marketing Channel 12.2 Neurological Disorder Drugs Distributors List 12.3 Neurological Disorder Drugs Customers 12.4 Neurological Disorder Drugs Supply Chain Analysis 13 Analyst's Viewpoints/Conclusions 14 Disclaimer